Mode
Text Size
Log in / Sign up

Diagnostic accuracy study compares HSV-1 IgG assays in adult male workers in QatarNew Herpes Test Could Change How Doctors Check for Infection

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider the Mindray CLIA for HSV-1 IgG testing, but confirm with a reference standard to minimize misclassification.

This is a diagnostic accuracy study assessing three HSV-1 IgG assays—Mindray CL-900i CLIA, HerpeSelect ELISA, and NovaLisa ELISA—against a Euroimmun Western blot reference standard. The scope was to evaluate seroprevalence and diagnostic performance using 400 archived serum samples from an adult male craft and manual worker cohort in Qatar.

The authors found comparable HSV-1 IgG seroprevalence across all assays: HerpeSelect 72.5%, Mindray 70.5%, NovaLisa 66.3%, and Western blot 66.5%, with all p > 0.05 indicating no statistically significant differences. The Mindray CLIA demonstrated the highest diagnostic performance, with sensitivity 95.7%, specificity 88.9%, accuracy 93.4%, and a kappa of 0.85, indicating strong agreement with the reference standard. HerpeSelect ELISA showed substantial agreement (kappa = 0.81), while NovaLisa ELISA had lower specificity.

The study did not report follow-up duration, safety events, or funding conflicts. Limitations include the single-cohort design and use of archived samples, which may limit generalizability. The authors note that confirmatory testing remains important to minimize misclassification, and the CLIA platform may support high-throughput settings.

Why testing accuracy matters

Doctors often use blood tests to check for this virus. But not all tests work the same way. Some might say you have it when you do not. Others might miss the infection entirely.

HSV-1 causes cold sores but can also cause genital infections.

It affects millions of people around the world. In some regions, most adults carry the virus without knowing it.

This makes accurate screening essential for public health.

The surprising shift in testing

For years, labs used slower methods to check blood samples. These tests were good, but they took time. Now, machines can process samples much faster.

But speed does not always mean better results.

The old way relied on manual steps that varied by technician. The new way uses automated systems designed for high volume.

Think of your immune system as a security guard. When the virus enters, the guard raises an alarm. The test looks for that alarm signal in your blood.

Different machines use different ways to spot that alarm.

Some look for specific antibodies that fight the virus. Others use light to detect the reaction.

The goal is to find the signal without false noise.

What the study actually tested

Researchers looked at 400 blood samples from men in Qatar. They compared three different lab machines against the best standard test. The goal was to see which machine was most reliable.

They focused on a population with high infection rates.

This helps show how the tests perform in real life.

The results showed all tests found similar infection rates. However, one automated machine performed the best. It caught almost all true cases without many false alarms.

This new test is not in clinics yet.

The automated system found 95.7% of the actual infections. It also correctly identified 88.9% of healthy people.

This means fewer people get scared by wrong results.

Older methods sometimes flagged healthy people as infected. That creates anxiety and leads to unnecessary follow-up visits.

Expert perspective on the results

Experts say this is a big step for busy hospitals. Faster tests mean quicker answers for patients. But they warn that one test is not enough on its own.

Confirmatory testing remains important to minimize misclassification.

If you need testing, talk to your doctor about the best option. Do not try to find this specific machine on your own. It is still part of ongoing research.

Your doctor will choose the right test for your situation.

Why you should wait for approval

This study only looked at one group of men in one country. Results might differ in other places or with different people. Small studies often need bigger checks to be sure.

We need to see if this works for women too.

Scientists will run more trials to confirm these results. Approval from health agencies takes time and careful review. We will know more when the data is complete.

Patience is key for safe medical progress.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Introduction: Herpes simplex virus type 1 (HSV-1) is highly prevalent worldwide, making accurate serological testing essential for both clinical diagnosis and epidemiological surveillance. Automated chemiluminescent immunoassays (CLIAs) offer operational advantages over enzyme-linked immunosorbent assays (ELISAs); however, their diagnostic performance relative to Western blot (WB) confirmation in high-prevalence settings remains insufficiently characterized. Hypothesis/Gap Statement: The comparative diagnostic accuracy of CLIA- and ELISA-based assays for HSV-1 IgG detection, when benchmarked against a WB reference standard in endemic populations, remains unclear. Aim: This study aimed to evaluate HSV-1 IgG seroprevalence and diagnostic performance of one CLIA and two ELISA platforms using Western blot as the reference method. Methodology: Four hundred archived serum samples from adult male craft and manual workers in Qatar were tested using the Mindray CL-900i CLIA, HerpeSelect ELISA, NovaLisa ELISA, and Euroimmun Western blot. Seroprevalence, diagnostic accuracy, and interassay agreement were assessed using WB as the reference standard, with equivocal and indeterminate results excluded from analysis. Results: HSV-1 IgG seroprevalence estimates were comparable across assays: HerpeSelect 72.5%, Mindray 70.5%, NovaLisa 66.3%, and Western blot 66.5%, with no statistically significant differences (all p > 0.05). The Mindray CLIA demonstrated the highest diagnostic performance (sensitivity 95.7%, specificity 88.9%, accuracy 93.4%) and strong agreement with Western blot ({kappa} = 0.85). HerpeSelect showed substantial agreement ({kappa} = 0.81), while NovaLisa exhibited lower specificity. Conclusion: CLIA- and ELISA-based assays produced comparable HSV-1 seroprevalence estimates in this high-prevalence population; however, diagnostic accuracy varied across platforms. The CLIA platform demonstrated the strongest agreement with Western blot, supporting its use in high-throughput settings, while confirmatory testing remains important to minimize misclassification.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.